BACKGROUND: Left ventricular (LV) abnormalities have been reported in cystic fibrosis (CF); however, it remains unclear if loss of cystic fibrosis transmembrane conductance regulator (CFTR) function causes heart defects independent of lung disease. METHODS: Using gut-corrected F508del CFTR mutant mice (ΔF508), which do not develop human lung disease, we examined in vivo heart and aortic function via 2D transthoracic echocardiography and LV catheterization. RESULTS: ΔF508 mouse hearts showed LV concentric remodeling along with enhanced inotropy (increased +dP/dt, fractional shortening, decreased isovolumetric contraction time) and greater lusitropy (-dP/dt, Tau). Aortas displayed increased stiffness and altered diastolic flow. β-adrenergic stimulation revealed diminished cardiac reserve (attenuated +dP/dt,-dP/dt, LV pressure). CONCLUSIONS: In a mouse model of CF, CFTR mutation leads to LV remodeling with alteration of cardiac and aortic functions in the absence of lung disease. As CF patients live longer, more active lives, their risk for cardiovascular disease should be considered.
BACKGROUND:Left ventricular (LV) abnormalities have been reported in cystic fibrosis (CF); however, it remains unclear if loss of cystic fibrosis transmembrane conductance regulator (CFTR) function causes heart defects independent of lung disease. METHODS: Using gut-corrected F508del CFTR mutant mice (ΔF508), which do not develop humanlung disease, we examined in vivo heart and aortic function via 2D transthoracic echocardiography and LV catheterization. RESULTS: ΔF508 mouse hearts showed LV concentric remodeling along with enhanced inotropy (increased +dP/dt, fractional shortening, decreased isovolumetric contraction time) and greater lusitropy (-dP/dt, Tau). Aortas displayed increased stiffness and altered diastolic flow. β-adrenergic stimulation revealed diminished cardiac reserve (attenuated +dP/dt,-dP/dt, LV pressure). CONCLUSIONS: In a mouse model of CF, CFTR mutation leads to LV remodeling with alteration of cardiac and aortic functions in the absence of lung disease. As CF patients live longer, more active lives, their risk for cardiovascular disease should be considered.
Authors: Da-yue Duan; Luis L H Liu; Nathan Bozeat; Z Maggie Huang; Sunny Y Xiang; Guan-lei Wang; Linda Ye; Joseph R Hume Journal: Acta Pharmacol Sin Date: 2005-03 Impact factor: 6.150
Authors: Simon G Williams; Mark Jackson; George Alastair Cooke; Diane Barker; Ashish Patwala; David Jay Wright; Khaled Albuoaini; Lip-Bun Tan Journal: Am Heart J Date: 2005-11 Impact factor: 4.749
Authors: J D Molkentin; J R Lu; C L Antos; B Markham; J Richardson; J Robbins; S R Grant; E N Olson Journal: Cell Date: 1998-04-17 Impact factor: 41.582
Authors: Hong Chen; Luis L Liu; Linda L Ye; Conor McGuckin; Susan Tamowski; Paul Scowen; Honglin Tian; Keith Murray; William J Hatton; Dayue Duan Journal: Circulation Date: 2004-08-02 Impact factor: 29.690
Authors: B G Zeiher; E Eichwald; J Zabner; J J Smith; A P Puga; P B McCray; M R Capecchi; M J Welsh; K R Thomas Journal: J Clin Invest Date: 1995-10 Impact factor: 14.808
Authors: Erik H Van Iterson; Courtney M Wheatley; Sarah E Baker; Wayne J Morgan; Eric M Snyder Journal: Heart Lung Date: 2016-04-01 Impact factor: 2.210
Authors: Jan K Nowak; Irena Wojsyk-Banaszak; Edyta Mądry; Andrzej Wykrętowicz; Patrycja Krzyżanowska; Sławomira Drzymała-Czyż; Agata Nowicka; Andrzej Pogorzelski; Ewa Sapiejka; Wojciech Skorupa; Mariusz Szczepanik; Aleksandra Lisowska; Jaroslaw Walkowiak Journal: Lung Date: 2017-06-23 Impact factor: 2.584
Authors: Alexander L Bisch; Courtney M Wheatley; Sarah E Baker; Elizabeth R Peitzman; Erik H Van Iterson; Theresa A Laguna; Wayne J Morgan; Eric M Snyder Journal: Clin Med Insights Circ Respir Pulm Med Date: 2019-03-29
Authors: Jakub Lagan; Josephine H Naish; Joshua Bradley; Christien Fortune; Charlie Palmer; David Clark; Erik B Schelbert; Matthias Schmitt; Rowland Bright-Thomas; Christopher A Miller Journal: Int J Cardiovasc Imaging Date: 2022-01-07 Impact factor: 2.357